Emerging Data in the Care of Multiple Myeloma
Source: 2017 American Society of Hematology Annual Meeting*

Conference Program

 

Module

In this online course, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the results and provide their perspective on the clinical applicability of key multiple myeloma studies presented at the Hematology 2017 annual meeting.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with myeloma
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of myeloma
  • Discuss new data on novel agents and therapeutic approaches for patients with myeloma
  • Plan optimal management approaches for stem cell transplantation based on emerging data and promising new agents
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with myeloma

Topics covered include:

  • Introduction
  • Smoldering Myeloma
  • Induction, Consolidation, and Maintenance
  • Relapsed/Refractory Myeloma
  • Supportive Care
  • Conclusions
 

Faculty

  • Shaji Kumar
    MD
    Sagar Lonial
    MD

Credit Information

  • Release Date:
    March 14, 2018
  • Expiration Date:
    March 13, 2019
  • Physicians:
    maximum of 3.0 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Shaji Kumar, MD


Department of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Celgene, Janssen, Merck, and Takeda and funds for research support from AbbVie, Celgene, Janssen, Merck, Roche, sanofi-aventis, and Takeda.
 

Sagar Lonial, MD


Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda and funds for research support from Celgene and Takeda.
 

Staff

Kristen M. Rosenthal, PhD


Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Megan Cartwright, PhD


Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
 

Anna Poppa, 


Editorial Contributor

Anna Poppa has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians and other healthcare providers involved in caring for patients with hematologic malignancies.


Goal

The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with multiple myeloma.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with myeloma
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of myeloma
  • Discuss new data on novel agents and therapeutic approaches for patients with myeloma
  • Plan optimal management approaches for stem cell transplantation based on emerging data and promising new agents
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve the outcomes for patients with myeloma
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from AbbVie, AstraZeneca, Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc., Seattle Genetics, and Takeda Oncology.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 3 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 14, 2018, through March 13, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.